Literature DB >> 26424305

Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.

Fumihiko Takahashi1, Masahide Goto, Yoshiki Wada, Naoyuki Hasebe.   

Abstract

A 28-year-old man was referred to our hospital for the treatment of congestive heart failure and severe hypertension. The patient was diagnosed with malignant phase hypertension based on the presence of marked hypertension with left ventricular hypertrophy, exudate retinopathy, and renal failure. Intensive therapy for hypertension and heart failure with a combination of antihypertensive drugs including nitroglycerin, nifedipine, eplerenone and candesartan successfully lowered his blood pressure and further improved the renal function. Eplerenone could be one of the choices of antihypertensive drugs in combination therapy in patients with malignant phase hypertension with progressive heart and renal failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26424305     DOI: 10.2169/internalmedicine.54.4425

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Role of Acetyl Salicylic Acid in Controlling the DOCA-Salt Induced Hypertension in Rats by Stimulating the Synthesis of r-Cortexin in the Kidney.

Authors:  Uttam Kumar Maji; Pradipta Jana; Mitali Chatterjee; Sanmay Karmakar; Arup Saha; Tamal Kanti Ghosh
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-01-06

2.  Role of aspirin activated nitric oxide synthase in controlling DOCA-salt-induced hypertension in rats through the stimulation of renal r-cortexin in kidney cortex cells.

Authors:  Uttam Kumar Maji; Tamal Kanti Ghosh; Mitali Chatterjee; Suman Bhattacharya; Sarbashri Bank; Pradipta Jana
Journal:  Int J Health Sci (Qassim)       Date:  2022 Jul-Aug

3.  Diffuse Alveolar Hemorrhaging with Hypertensive Emergency: A Rare but Important Cause of Hemoptysis.

Authors:  Ayana Suzuki; Naoki Nakagawa; Keisuke Maruyama; Motoki Matsuki; Naoyuki Hasebe
Journal:  Intern Med       Date:  2019-02-01       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.